Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887968 | 0.84 | AOC3 (0.52) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL2068304 | 0.80 | AOC3 (0.74) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL2788439 | 0.79 | SMN1; SMN2 (0.69) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4880248 | 0.78 | AOC3 (0.57) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL5179460 | 0.78 | AOC3 (0.57) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4886988 | 0.76 | SMN1; SMN2 (0.65) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL971493 | 0.76 | AOC3 (0.67) | AOC3SMN1; SMN2KMT2AMAOBNPC1 | |
| SCHEMBL4893124 | 0.76 | KDM4E (0.49) | AOC3SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL4893118 | 0.76 | KDM4E (0.49) | AOC3SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL8430108 | 0.76 | AOC3 (0.76) | AOC3SMN1; SMN2KMT2AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1791835-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006028269-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 163/4885SMN1; SMN2 2277/4885KMT2A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.